StockData

Scholar Rock vs Tectonic Therapeutic

SRRK and TECX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SRRK and TECX compare

Scholar Rock is the larger company, worth 13 times as much as Tectonic Therapeutic ($5.3B against $413M).

Tectonic Therapeutic scores higher on the StockData Score (7 against 2 for Scholar Rock), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSRRKTECX
Size and price
Market cap$5.3B$413M
Share price$43.20$21.14
Change, 1 year40.2%12.1%
Change, 5 years46.3%−58.6%
Beta (5Y)1.501.54
Employees28960
StockData Score
Total score27 (better)
Valuation score01 (better)
Growth score00
Performance score01 (better)
Health score25 (better)
Dividend score00
Valuation
P/S9231×–
P/B31.2×1.8× (better)
FCF yield−5.9% (better)−16.8%
Profitability
Operating margin−71732%–
Net margin−72563%–
FCF margin−54371%–
Return on equity−200%−35.5% (better)
Financial health
Debt / equity1.16 (better)0.00
Interest coverage−29.2× (better)−3216.4×
Current ratio5.4119.71 (better)
Altman Z-score4.2215.19 (better)
Piotroski F-score14 (better)
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Buyback yield−3.1%–
Shareholder yield−3.1%0.00% (better)
Ownership
Held by institutions114%71.4%
Held by insiders28.9%42.8%
Insider net buying, 12 months−$7.4M−$416K (better)
Short interest, % of float27.1%21.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.